Stockreport

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc.  (ATOS) 
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.atossagenetics.com
PDF (Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving 75 % of planned treatment in I-SPY-2 Phase 2 Trial Low dose (Z)-endoxifen was wel [Read more]